ASTELLAS PHARMA, INC. (ALPMF)
Clinical trial NCT06901531 updates: 1. completion date: 2028-09-30 → 2027-03-31 2. primary completion date: 2028-09-30 → 2027-03-31
Clinical trial NCT06901531 updates: 1. completion date: 2028-09-30 → 2027-03-31 2. primary completion date: 2028-09-30 → 2027-03-31
Clinical trial NCT07669077: start date: 2026-06-26 → 2026-06-23.
Clinical trial NCT05488314: primary completion date: 2026-06-09 → 2027-04-28.
Clinical trial NCT05045820 updates: 1. completion date: 2026-06-20 → 2026-08-20 2. enrollment: 60 → 106 participants 3. enrollment type: ESTIMATED → ACTUAL
Clinical trial NCT03383458 updates: 1. completion date: 2031-02-27 → 2031-05-27 2. primary completion date: 2026-02-27 → 2026-05-27
Clinical trial NCT07581002 updates: 1. status: NOT_YET_RECRUITING → RECRUITING 2. start date: 2026-07-22 → 2026-06-30
Clinical trial NCT07586202: start date: 2026-07-17 → 2026-07-28.
General Announcement: COMPLETION OF DISPOSAL OF CHEMICAL TANKER - MT SINAR MENDAWAI
SEALSQ Launches Commercial Phase of Miraex Quantum Photonics Technology Following Strategic Acquisition
Law Offices of Howard G. Smith Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders To Inquire About Securities Fraud Class Action